| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM197811232992102 |
| P953 | full work available at URL | http://www.nejm.org/doi/pdf/10.1056/NEJM197811232992102 |
| P698 | PubMed publication ID | 309095 |
| P2093 | author name string | D. M. Ilstrup | |
| Donadio JV Jr | |||
| K. E. Holley | |||
| J. V. Donadio | |||
| R. H. Ferguson | |||
| P2860 | cites work | Mayo Clin Proc | Q6538184 |
| Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis | Q30449890 | ||
| Criteria for the classification of systemic lupus erythematosus--status 1972. | Q33461204 | ||
| The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor). | Q36270989 | ||
| Immune potential in human uraemia. 1. Relationship of glomerular filtration rate to depression of immune potential | Q36601763 | ||
| Detection of circulating immune complexes in patients with glomerulonephritis | Q40849732 | ||
| The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 | ||
| Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months | Q66904185 | ||
| Lupus nephritis. Clinical course as related to morphologic forms and their transitions | Q67544571 | ||
| Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine | Q68535020 | ||
| The Effect of Treatment with Prednisone and Nitrogen Mustard on the Renal Lesions and Life Span of Patients with Lupus Glomerulonephritis | Q69266428 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lupus nephritis | Q1621830 |
| P304 | page(s) | 1151-1155 | |
| P577 | publication date | 1978-11-01 | |
| 1978-11-23 | |||
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide | |
| P478 | volume | 299 |
| Q46484877 | A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis |
| Q38774602 | A review of the rational use of corticosteroids |
| Q40173227 | Acute Glomerulonephritis: A Clinical Overview |
| Q40300190 | Antirheumatic drugs: clinical pharmacology and therapeutic use. |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q37892917 | Clearing the complexity: immune complexes and their treatment in lupus nephritis |
| Q60128791 | Clinical features and renal outcome in lupus patients with diffuse crescentic glomerulonephritis |
| Q40154586 | Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases |
| Q37949332 | Current treatment recommendations for lupus nephritis |
| Q40197212 | Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses |
| Q34095231 | Cyclophosphamide and lupus nephritis: when, how, for how long? |
| Q34226984 | Cyclophosphamide for the treatment of systemic lupus erythematosus |
| Q36054857 | Cyclophosphamide in lupus nephritis |
| Q40807892 | Cyclophosphamide treatment in polyarteritis nodosa |
| Q24200954 | Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus |
| Q24246092 | Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus |
| Q38372154 | Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study |
| Q41484969 | Diagnosis and management of glomerular diseases |
| Q38059445 | Diagnosis and treatment of lupus nephritis flares--an update. |
| Q36462580 | Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? |
| Q37804548 | Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review |
| Q57807541 | Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report |
| Q26866290 | Glomerular disease: perspectives on maintenance therapy in lupus nephritis |
| Q40883177 | Immunosuppressive drug therapy in lupus nephritis |
| Q40181272 | Immunosuppressive therapy in the treatment of autoimmune diseases |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q34990100 | Infections in the immunocompromised rheumatologic patient |
| Q41475106 | Infectious complications of immunosuppressive therapy in patients with rheumatic diseases |
| Q54352606 | Intermittent intravenous cyclophosphamide therapy for lupus nephritis. |
| Q34124711 | Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis |
| Q36840240 | Kidney disease in systemic lupus erythematosus |
| Q37586440 | Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV. |
| Q46467090 | Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. |
| Q43031095 | Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. |
| Q73604873 | Lupus nephritis |
| Q95592748 | Lupus nephritis |
| Q36054851 | Lupus nephritis flares |
| Q38608138 | Lupus nephritis: an update |
| Q36085856 | Lupus nephritis: induction therapy |
| Q68125366 | Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL) |
| Q26998390 | Lupus nephritis: the evolving role of novel therapeutics |
| Q46416350 | Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide |
| Q37800295 | Major lupus organ involvement: severe lupus nephritis |
| Q28316622 | Mesna side effects which imitate vasculitis |
| Q44397965 | Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice. |
| Q54260329 | Mycophenolate versus Cyclophosphamide for Lupus Nephritis. |
| Q34481499 | Novel approaches in the treatment of lupus nephritis |
| Q69791000 | Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus |
| Q37392125 | Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease |
| Q43959861 | Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine |
| Q41165180 | Outcome of silent lupus nephritis |
| Q79864046 | Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy |
| Q71877365 | Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone |
| Q39758027 | Pro: Cyclophosphamide in lupus nephritis |
| Q70240417 | Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis |
| Q37146440 | Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy |
| Q57945954 | References |
| Q66940680 | Regulation of secondary antibody responses in rodents. I. Potentiation of IgG production by cyclophosphamide |
| Q40664132 | Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal |
| Q41317916 | Renal flare prediction and prognosis in lupus nephritis Hispanic patients |
| Q40646509 | Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies |
| Q55215256 | Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. |
| Q46082712 | Serial assessment of glomerular filtration rate in lupus nephropathy |
| Q87705292 | Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study |
| Q55040154 | Systematic Review and the External Validity of Randomized Controlled Trials in Lupus Nephritis. |
| Q49486030 | Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis |
| Q68862114 | Systemic lupus erythematosus |
| Q40506580 | Systemic lupus erythematosus--disease management |
| Q72414027 | The Use of Cyclophosphamide in the Treatment of Multiple Sclerosis |
| Q39536412 | The coexistence of rheumatoid arthritis and systemic lupus erythematosus |
| Q34447281 | The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone |
| Q38829637 | The safety of pharmacological treatment options for lupus nephritis |
| Q39749422 | The treatment of lupus nephritis |
| Q36206136 | Therapeutic aspects. Immunosuppression in established humoral responses |
| Q36790803 | Thirty years of cyclophosphamide: assessing the evidence |
| Q24202572 | Treatment for lupus nephritis |
| Q24247408 | Treatment for lupus nephritis |
| Q40906582 | Treatment of lupus nephritis: a meta-analysis of clinical trials |
| Q28372716 | Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression |
| Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q35201234 | Treatment of severe proliferative lupus nephritis: the current state |
| Q68931618 | Treatment of systemic lupus erythematosus |
| Q74022703 | Treatment of systemic lupus erythematosus |
| Q69914555 | [Drug treatment of chronic glomerulonephritis: pro] |
| Q73338674 | [Treatment of lupus nephritis in children] |
| Q40699216 | n-3 fatty acids and renal diseases |
Search more.